KAITLIN KING: Open Payments
NPI 1801325162 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 42 payments from 13 companies in 2025. Trend: 2023 $863 · 2024 $1,345 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $255 |
| Novo Nordisk Inc | 11 | $183 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $92 |
| Aimmune Therapeutics, Inc. | 3 | $71 |
| PFIZER INC. | 4 | $67 |
| ABBVIE INC. | 2 | $58 |
| Boston Scientific Corporation | 1 | $43 |
| Lilly USA, LLC | 2 | $37 |
| Astellas Pharma US Inc | 1 | $30 |
| Exact Sciences Corporation | 1 | $19 |
Products named: FARXIGA, XIFAXAN, AIRSUPRA, ZENPEP, Ozempic, Rybelsus, NURTEC ODT, Wegovy.
Industry payments across AZ — which companies pay providers there.
